Huons Receives IND Approval for Phase 1 Clinical Trial of Dry Eye Treatment 'HUC1-394'
Huons is targeting the dry eye disease market through the development of a new mechanism of action for dry eye treatment.
Huons Co., Ltd. announced on the 8th that it has received approval for the clinical trial application (IND) of the dry eye treatment 'HUC1-394 (NCP112)' from the Ministry of Food and Drug Safety. Huons had previously applied for the Phase 1 clinical trial plan for 'HUC1-394' in Korea in June of last year.
HUC1-394 is a peptide-based eye drop licensed from Novacell Technology Co., Ltd. It significantly improves keratoconjunctivitis caused by dry eye disease, restores damaged corneas, and reduces inflammation and the possibility of side effects, which are major causes of dry eye disease.
Huons plans to evaluate the safety, local tolerability, and pharmacokinetic characteristics of single and repeated stepwise dose escalation administration of HUC1-394 eye drops in 60 adult subjects.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- [Lee Jaemyung Administration 1 Year] 300,000 Benefit from Rural Basic Income, K-Food Hits 'All-Time High' Last Year
- "Groups of 5 or More Now Restricted"... Unrelenting Running Craze Leaves Citizens and Police Exhausted
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
A Huons representative stated, "Through this clinical trial, we plan to confirm the safety, local tolerability, and pharmacokinetic characteristics after administration of HUC1-394 eye drops," adding, "We expect to provide a new mechanism-based treatment option for patients with dry eye disease."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
